Abstract 239P
Background
Oral cancer surgery includes radical resections of the mandible and tongue, affecting the functional swallowing outcomes. However, risk factors and swallowing outcomes are not the same for all subsites of oral cancer. The present study aimed to assess the difference in patient-reported swallowing function and quality of life after primary surgical resection in tongue vs bucco- alveolar complex (BAC) malignancies.
Methods
Study included oral cancer patients requiring mandibulectomy for BAC subsite and at least hemi-glossectomy for tongue, all reconstructed with pedicle flaps at our institute from Dec 2019 to Dec 2021. The Sydney Swallow Questionnaire (SSQ) and Functional oral intake scale (FOIS) were used to assess swallowing outcomes after six months DFS. WHO BREF questionnaire was used to assess health-related quality of life.
Results
The final analysis included 66 patients. The median age was 48 yrs and majority are males (92.4%). BAC constituted 63.6%, and tongue lesions were 36.4%. Tumours with cT3 and T4 are 59% of BAC and 46% of tongue lesions. In BAC, 85% underwent segmental mandibulectomy, and 87% of tongue lesions were treated with hemiglossectomy. 85.7% of BAC and 92% of tongue lesions received adjuvant radiation. Trismus and xerostomia were present in 71.4%, 85% in BAC and 50%, 75% in tongue lesions, respectively. The mean SSQ score was (282.6, SD= 95), (222.5, SD=96) BAC and tongue, respectively. Advanced T stage (p=0.07), Multimodality treatment (p=0.01), lymphedema (p=0.03), Trismus (p=0.01), Dysgeusia (p=0.01), xerostomia (p=0.01) in BAC lesions. Advanced T stage (p=0.007), Multimodality treatment (p=0.04), lymphedema (p=0.03), Dysgeusia (p=0.01) in tongue lesions are associated with poor outcomes. Almost 88% of BAC lesions required special food preparation for swallowing (FOIS 5). However, only 16.7% of tongue lesions required special preparation. There is a trend toward better health-related quality of life (HRQOL) in tongue lesions.
Conclusions
There is a difference in swallowing results between tongue and BAC cancers. Tongue lesions had more reasonable swallowing outcomes. However, overall, HRQOL is comparable between both subsites.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03